Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TRACON Pharmaceuticals, Inc. (TCON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8900-0.2800 (-8.83%)
At close: 4:00PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference

    SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fi

  • GlobeNewswire

    TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial results for the third quarter ended September 30, 2021. The Company will host a conferen

  • GlobeNewswire

    TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021

    SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its third quarter 2021 financial and operating results after the close of U.S.

Advertisement
Advertisement